말기 만성 콩팥병 환자에서 새로운 투석치료

키워드

참고문헌 (99)

1. Foley RN, "End-stage renal disease in the United States: an update from the United States Renal Data System", J Am Soc Nephrol, 18, pp.2644~2648 (2007)
2. Nissenson AR, "Clinical dialysis. 4th ed", pp.1~ (2006), The McGraw-Hill
3. Kaplow LS, "Profound neutropenia during the early phase of hemodialysis", JAMA, 203, pp.1135~1137 (1968)
4. Craddock PR, "Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis", N Engl J Med, 296, pp.769~774 (1977)
5. Craddock PR, "Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes", J Clin Invest, 59, pp.879~888 (1977)
6. Davenport A, "The role of dialyzer membrane flux in bioincompatibility", Hemodial Int, 12(2), pp.S29~S33 (2008)
7. Misra M, "Basic mechanisms governing solute and fluid transport in hemodialysis", Hemodial Int, 12(2), pp.S25~S28 (2008)
8. Krane V, "Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis", Am J Kidney Dis, 49, pp.267~275 (2007)
9. Delmez JA, "Hemodialysis (HEMO) Study Group. Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study", Am J Kidney Dis, 47, pp.131~138 (2006)
10. Cheung AK, "Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study", J Am Soc Nephrol, 17, pp.546~555 (2006)
11. Petrie JJ, "Review Article: is it time to embrace haemodiafiltration for centre-based haemodialysis?", Nephrology, 13, pp.269~277 (2008)
12. Gejyo F, "Current clinical and pathogenetic understanding of beta2-m amyloidosis in long-term haemodialysis patients", Nephrology (Carlton), 8, pp.S45~S49 (2003)
13. Ahrenholz PG, "Dialysis membrane-dependent removal of middle molecules during hemodiafiltration: the beta2-microglobulin", albumin relationship, 2004, pp.62, 21~28
14. Henderson LW, "Kinetics of hemodiafiltration. II. Clinical characterization of a new blood cleansing modality", J Lab Clin Med, 85, pp.372~391 (1975)
15. jSchaefer K, "Optimum dialysis treatment for patients over 60 years with primary renal disease. Survival data and clinical results from 242 patients treated either by haemodialysis or haemofiltration", Proc Eur Dial Transplant Assoc Eur Ren Assoc, 21, pp.510~523 (1985)
16. Baldamus CA, "Quellhorst E. Outcome of long-term hemofiltration", Kidney Int Suppl, 17, pp.S41~S46 (1985)
17. Locatelli F, "Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto", Kidney Int, 55, pp.286~293 (1999)
18. Locatelli F, "Removal of small and middle molecules by convective techniques", Nephrol Dial Transplant, 15(2), pp.37~44 (2000)
19. Maduell F, "Hemodiafiltration", Hemodial Int, 9, pp.47~55 (2005)
20. Ledebo I, "On-line hemodiafiltration: technique and therapy", Adv Ren Replace Ther, 6, pp.195~208 (1999)
21. Kerr PB, "Comparison of hemodialysis and hemodiafiltration: a long-term longitudinal study", Kidney Int, 41, pp.1035~1040 (1992)
22. Zehnder C, "Hemodiafiltration--a new treatment option for hyperphosphatemia in hemodialysis patients", Clin Nephrol, 52, pp.152~159 (1999)
23. Spalding EM, "Phosphate kinetics during hemodialysis: Evidence for biphasic regulation", Kidney Int, 61, pp.655~667 (2002)
24. 김진영, "만성 신부전 환자에서 혈액투석여과법의 임상적 유용성", The Korean Journal of Nephrology, 24(6), pp.885~893 (2005), 대한신장학회
25. 신준암, "고유량 혈액투석에서 온라인 혈액여과투석법으로 전환 후임상 소견과 beta 2-microglobulin 및 oxidized LDL의 변화", The Korean Journal of Nephrology, 27(1), pp.62~69 (2008), 대한신장학회
26. Dember LM, "Dialysis-related amyloidosis: late finding or hidden epidemic?", Semin Dial, 19, pp.105~109 (2006)
27. Wiesholzer M, "Inappropriately high plasma leptin levels in obese haemodialysis patients can be reduced by high flux haemodialysis and haemodiafiltration", Clin Sci (Lond), 94, pp.431~435 (1998)
28. Lonnemann G, "A switch to high-flux helixone membranes reverses suppressed interferon-gamma production in patients on low-flux dialysis", Blood Purif, 21, pp.225~231 (2003)
29. Maduell F, "Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low- and high-flux hemodialysis", Am J Kidney Dis, 40, pp.582~589 (2002)
30. Ward RA, "A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study", J Am Soc Nephrol, 11, pp.2344~2350 (2000)
31. Donauer J, "Reduction of hypotensive side effects during online- haemodiafiltration and low temperature haemodialysis", Nephrol Dial Transplant, 18, pp.1616~1622 (2003)
32. Munoz R, "Online hemodiafiltration: 4 years of clinical experience", Hemodial Int, 10(1), pp.S28~S32 (2006)
33. Stenvinkel P, "Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome)", Nephrol Dial Transplant, 15, pp.953~960 (2000)
34. Arduino MJ, "The effects of endotoxin-contaminated dialysate and polysulfone or cellulosic membranes on the release of TNF alpha during simulated dialysis", Artif Organs, 19, pp.880~886 (1995)
35. Lonnemann G, "Permeability of dialyzer membranes to TNF alpha-inducing substances derived from water bacteria", Kidney Int, 42, pp.61~68 (1992)
36. Pereira BJ, "Diffusive and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes", Kidney Int, 47, pp.603~610 (1995)
37. Schindler R, "Induction of interleukin-1 and interleukin-1 receptor antagonist during contaminated in-vitro dialysis with whole blood", Nephrol Dial Transplant, 11, pp.101~108 (1996)
38. Tielemans C, "Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis", Kidney Int, 49, pp.236~243 (1996)
39. Group European Best Practice Guidelines Working, "European Best Practice Guidelines for haemodialysis. Section IV. Dialysis fluid purity", Nephrol Dial Transplant, 17(7), pp.45~62 (2002)
40. Arizono K, "Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis", Blood Purif, 22(2), pp.26~29 (2004)
41. Schindler R, "Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens", Clin Nephrol, 59, pp.447~454 (2003)
42. Schindler R, "The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis", Nephron, 68, pp.229~233 (1994)
43. Lonnemann G, "Pyrogen retention by highly permeable synthetic membranes during in vitro dialysis", Artif Organs, 25, pp.951~960 (2001)
44. Matsuhashi N, "Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients", Nephron, pp.601~604 (2002)
45. Schiffl H, "Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters", Nephrol Dial Transplant, 16, pp.1863~1869 (2001)
46. Sitter T, "Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients", Nephrol Dial Transplant, 15, pp.1207~1211 (2000)
47. Furuya R, "Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients", Blood Purif, 23, pp.311~316 (2005)
48. Gerdemann A, "Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality", Nephrol Dial Transplant, 17, pp.1045~1049 (2002)
49. Schouten WE, "Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis", Nephrol Dial Transplant, 15, pp.379~384 (2000)
50. Bilgic A, "Clinical outcome after transfer from peritoneal dialysis to hemodialysis", Adv Perit Dial, 22, pp.94~98 (2006)
51. Smit W, "Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a crosssectional study", Perit Dial Int, 24, pp.562~570 (2004)
52. Williams JD, "Morphologic changes in the peritoneal membrane of patients with renal disease", J Am Soc Nephrol, 13, pp.470~479 (2002)
53. Brulez HF, "In vitro compatibility of a 1.1% amino acid containing peritoneal dialysis fluid with phagocyte function", Adv Perit Dial, 10, pp.241~244 (1994)
54. Ha H, "Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation", Perit Dial Int, 20(5), pp.S10~S18 (2000)
55. Plum J, "Osmotic agents and buffers in peritoneal dialysis solution: monocyte cytokine release and in vitro cytotoxicity", Am J Kidney Dis, 30, pp.413~422 (1997)
56. Posthuma N, "Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin", Perit Dial Int, 21, pp.43~51 (2001)
57. Jorres A, "In vitro biocompatibility evaluation of a novel bicarbonate-buffered amino- acid solution for peritoneal dialysis", Nephrol Dial Transplant, 12, pp.543~549 (1997)
58. Jorres A, "Passlick-Deetjen J. In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions", Nephrol Dial Transplant, 9, pp.785~790 (1994)
59. Witowski J, "Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells", J Am Soc Nephrol, 12, pp.2434~2441 (2001)
60. Park SH, "Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat", Perit Dial Int, 24, pp.115~122 (2004)
61. Inagi R, "Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis", FEBS Lett, 463, pp.260~264 (1999)
62. Dawnay AB, "Glycation and advanced glycation end-product formation with icodextrin and dextrose", Perit Dial Int, 17, pp.52~58 (1997)
63. Boulanger E, "The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products", Nephrol Dial Transplant, 19, pp.2208~2216 (2004)
64. Williams JD, "The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane", Kidney Int, 66, pp.408~418 (2004)
65. The Bicarbonate, "Lactate Study Group", Tranaeus AA long-term study of a bicarbonate, Perit Dial Int, pp.2000, 20[DOI]
66. Rippe B, "Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products", Kidney Int, 59, pp.348~357 (2001)
67. Jones S, "Bicarbonate", lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels, 2001, pp.59, 1529~1538
68. Fusshoeller A, "Biocompatibility pattern of a bicarbonate", lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study, 2004, pp.19, 2101~2106
69. "Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance)", Perit Dial Int, 25, pp.248~255 (2005)
70. Kim YL, "Effects of new peritoneal dialysis solutions", Korean J Nephrol, 23(2), pp.S454~S460 (2004)
71. Feriani M, "Randomized long-term evaluation of bicarbonate-buffered CAPD solution", Kidney Int, 54, pp.1731~1738 (1998)
72. Coles GA, "A controlled trial of two bicarbonate-containing dialysis fluids for CAPD--final report", Nephrol Dial Transplant, 13, pp.3165~3171 (1998)
73. Carrasco AM, "Acidosis correction with a new 25 mmol", l bicarbonate, l lactate peritoneal dialysis solution, pp.Perit Dial Int, 2001[DOI]
74. Haas S, "Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis", J Am Soc Nephrol, 14, pp.2632~2638 (2003)
75. Schmitt CP, "Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children", Kidney Int, 61, pp.1527~1536 (2002)
76. Cancarini GC, "Clinical evaluation of a peritoneal dialysis solution with 33 mmol", L bicarbonate, 1998, pp.18, 576~582
77. Lee HY, "Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome", Nephrol Dial Transplant, 21, pp.2893~2899 (2006)
78. Moberly JB, "Pharmacokinetics of icodextrin in peritoneal dialysis patients", Kidney Int Suppl, 81, pp.S23~S33 (2002)
79. Finkelstein F, "Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration", J Am Soc Nephrol, 16, pp.546~554 (2005)
80. Posthuma N, "Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance", Nephrol Dial Transplant, 12, pp.550~553 (1997)
81. Woodrow G, "Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis", Nephrol Dial Transplant, 14, pp.1530~1535 (1999)
82. Ota K, "Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients", Perit Dial Int, 23, pp.356~361 (2003)
83. Gokal R, "Newer peritoneal dialysis solutions", Adv Ren Replace Ther, 7, pp.302~309 (2000)
84. Krediet RT, "Clinical advantages of new peritoneal dialysis solutions", Nephrol Dial Transplant, 17(3), pp.16~18 (2002)
85. Wolfson M, "A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis", Am J Kidney Dis, 40, pp.1055~1065 (2002)
86. Konings CJ, "Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study", Kidney Int, 63, pp.1556~1563 (2003)
87. Davies SJ, "Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial", J Am Soc Nephrol, 14, pp.2338~2344 (2003)
88. Bredie SJ, "Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism", Perit Dial Int, 21, pp.275~281
89. Gursu EM, "The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients", Clin Nephrol, 66, pp.263~268 (2006)
90. Furuya R, "Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients", Nephrol Dial Transplant, 21, pp.494~498 (2006)
91. Canbakan M, "Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients", Ren Fail, 29, pp.289~293 (2007)
92. 유태현, "자동 복막투석의 임상적 유용성", The Korean Journal of Nephrology, 24(2), pp.280~288 (2005), 대한신장학회
93. Lee HY, "Automated peritoneal dialysis", Korean J Nephrol, 18(1), pp.S55~S62 (1999)
94. Raj DS, "Role of APD in compliance with therapy", Semin Dial, 15, pp.434~436 (2002)
95. Diaz-Buxo JA, "Automated peritoneal dialysis therapies--patient selection and dialysis prescription", Adv Perit Dial, 5, pp.207~211 (1989)
96. Brunkhorst R, "Clinical experience with home automated peritoneal dialysis", Kidney Int Suppl, 48, pp.S25~S30 (1994)
97. de Fijter CW, "Antibacterial peritoneal defence in automated peritoneal dialysis: advantages of tidal over continuous cyclic peritoneal dialysis?", Nephrol Dial Transplant, 9, pp.156~162 (1994)
98. Huang JW, "Comparison of infectious complications in peritoneal dialysis patients using either a twin-bag system or automated peritoneal dialysis", Nephrol Dial Transplant, 16, pp.604~607 (2001)
99. Holley JL, "Continuous cycling peritoneal dialysis is associated with lower rates of catheter infections than continuous ambulatory peritoneal dialysis", Am J Kidney Dis, 16, pp.133~136 (1990)

관련 논문AI추천